Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
STARLITE for Unresectable High-Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 24
- Registration Number
- NCT06428045
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide
- Conditions
- Interventions
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT02957864
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱OLVG, Amsterdam, Netherlands
🇳🇱Maasstad ziekenhuis, Rotterdam, Netherlands
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02182765
Determining the Effect of Abacavir on Platelet Activation
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 23
- Registration Number
- NCT01886638
- Locations
- 🇦🇺
Alfred Health, Melbourne, Victoria, Australia
Abacavir and Lamivudine PK in Children
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2016-02-22
- Target Recruit Count
- 30
- Registration Number
- NCT01656122
- Locations
- 🇹🇭
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand
Study of Options for Second-Line Effective Combination Therapy (SELECT)
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 515
- Registration Number
- NCT01352715
- Locations
- 🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
🇿🇦Soweto ACTG CRS (12301), Johannesburg, South Africa
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 12
- Registration Number
- NCT00915655
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
- Conditions
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 54
- Registration Number
- NCT00799864
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 29
- Registration Number
- NCT00765271
- Locations
- 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom
Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00647244
- Locations
- 🇩🇰
Aarhus University Hospital, Århus N, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.